Nicola Heffron Biography and Net Worth

COO of 2seventy bio

Nicola Heffron is chief operating officer at 2seventy bio. Previously, Nicola was at bluebird bio for almost two years, where she held multiple leadership positions, most recently as chief operating officer of the oncology business unit. She has accumulated over 25 years of experience across R&D, global commercial, and local operational P&L and marketing strategy roles. She led the commercial launch for a global franchise across 16 rare and specialty brands. Most recently Nicola led the Global Myeloid Commercial team at Celgene. Before this, she ran the Global Internal Medicine Franchise for Shire and held a number of leadership roles in R&D and Commercial at global, regional, and affiliate levels at GSK and Eli Lilly. A qualified pharmacist, Nicola holds an M.B.A. from the University of Warwick in the UK.

What is Nicola Heffron's net worth?: The estimated net worth of Nicola Heffron is at least $349,593.44 as of February 7th, 2023. Ms. Heffron owns 89,182 shares of 2seventy bio stock worth more than $349,593 as of November 14th. This net worth approximation does not reflect any other investments that Ms. Heffron may own. Learn More about Nicola Heffron's net worth.
How do I contact Nicola Heffron?: The corporate mailing address for Ms. Heffron and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on Nicola Heffron's contact information.
Has Nicola Heffron been buying or selling shares of 2seventy bio?: Nicola Heffron has not been actively trading shares of 2seventy bio over the course of the past ninety days. Most recently, Nicola Heffron sold 60 shares of the business's stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $14.70, for a transaction totalling $882.00. Following the completion of the sale, the chief operating officer now directly owns 89,182 shares of the company's stock, valued at $1,310,975.40. Learn More on Nicola Heffron's trading history.
Who are 2seventy bio's active insiders?: 2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.
Are insiders buying or selling shares of 2seventy bio?: During the last twelve months, 2seventy bio insiders bought shares 2 times. They purchased a total of 630,000 shares worth more than $3,143,100.00. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 144,965 shares worth more than $564,664.26. The most recent insider tranaction occured on August, 14th when insider Jessica Snow sold 7,816 shares worth more than $33,765.12. Insiders at 2seventy bio own 7.2% of the company. Learn More about insider trades at 2seventy bio.
Information on this page was last updated on 8/14/2024.

Nicola Heffron Insider Trading History at 2seventy bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2023	Sell	60	$14.70	$882.00	89,182
1/11/2023	Sell	128	$10.63	$1,360.64	89,242
1/9/2023	Sell	584	$10.33	$6,032.72	89,370
12/5/2022	Sell	272	$15.43	$4,196.96	89,954
11/21/2022	Sell	7,697	$13.97	$107,527.09	90,226
2/7/2022	Sell	1,636	$16.01	$26,192.36
2/4/2022	Sell	467	$15.41	$7,196.47
12/7/2021	Sell	257	$31.06	$7,982.42

Nicola Heffron Buying and Selling Activity at 2seventy bio

2seventy bio Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.92

$3.90

$4.32

50 Day Range

MA: $4.74

$4.13

$5.21

2 Week Range

Now: $3.92

$1.53

$6.40

Volume

283,585 shs

Average Volume

313,004 shs

Market Capitalization

$202.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.